#AAN2018 – Early Data Supports Clinical Trial Now Testing IONIS-MAPTRx in Alzheimer’s Patients
An injection of IONIS-MAPTRx resulted in a 70 percent decrease in tau protein produced in the brains of non-human primates, researchers at Ionis Pharmaceuticals, the potential treatment’s maker, are reporting. These positive pre-clinical findings helped in the design of a first clinical study, now underway and enrolling, that will…